Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A congenital autosomal dominant immune deficiency characterized by abnormal retention of mature neutrophils in the bone marrow (myelokathexis) and occasional hypogammaglobulinemia, associated with an increased risk for bacterial infections and a susceptibility to human papillomavirus (HPV) induced lesions (cutaneous warts, genital dysplasia and invasive mucosal carcinoma).
Features include: Abnormal female external genitalia morphology, Decreased circulating immunoglobulin concentration, Bronchiectasis, and Abnormal bone marrow cell morphology and 8 more.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Blood and immune system | 3 | Recurrent bacterial infections, Recurrent upper respiratory tract infections, Decreased total neutrophil count |
Lungs and breathing | 2 | Bronchiectasis, Recurrent upper respiratory tract infections |
Bones and joints | 2 | Abnormal bone marrow cell morphology, Bone marrow hypercellularity |
CXCR4 encodes C-X-C motif chemokine receptor 4 (352 aa). Receptor for the C-X-C chemokine CXCL12/SDF-1 that transduces a signal by increasing intracellular calcium ion levels and enhancing MAPK1/MAPK3 activation. Highest expression in Whole Blood (419.9 TPM) and Spleen (410.7 TPM).
WHIM syndrome 1 is associated with mutations in the CXCR4 gene on chromosome 2.
The CXCR4 protein participates in Expression of CXCR4 in definitive endoderm, Expression of CXCR4 in primordial germ cells, and Receptors CXCR4 and 7 bind CXCL12 ligand pathways.
CXCR4 is classified as a druggable target (Cell Surface, Clinically Actionable, Drug Resistance, Druggable Genome, External Side Of Plasma Membrane, and G Protein Coupled Receptor categories) with score 6.3.
Genetic testing for CXCR4 is available. Testing is considered confirmatory for diagnosis.
No approved treatments are currently available for WHIM syndrome 1. An additional 1 compound holds orphan drug designation.
While no drugs are FDA-approved specifically for WHIM syndrome 1, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.
The following drugs have received orphan drug designation from the FDA for WHIM syndrome 1. Orphan designation reflects regulatory interest and does not indicate approval for treatment.
Brand Name | Generic Name | Sponsor | Designated | Exclusivity End | Designation Status |
|---|---|---|---|---|---|
Xolremdi | mavorixafor | X4 Pharmaceuticals, Inc. | 2018 | 2031 | Designated (drug approved for other indication) |
Xolremdi is referenced in active clinical trials for WHIM syndrome 1 (designated 2018).
Gene therapy approaches for WHIM syndrome 1 have been reported in the published literature.
1 trial found
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
1 clinical trial registered. Interventions under study include drug therapy. Pipeline includes 1 PHASE3. Research is primarily industry-sponsored.
44 publications have been identified in PubMed for WHIM syndrome 1. Research spans Review / Meta-Analysis (23%), Case Report / Case Series (23%), and Other (20%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 10 | 23% |
Patient case studies | 10 | 23% |
Other research | 9 | 20% |
Laboratory research | 9 | 20% |
New treatment approaches | 4 | 9% |
Clinical study results | 1 | 2% |
Disease patterns and progression | 1 | 2% |
Quijada-Freire A (2026). [PMID: 42118136](https://pubmed.ncbi.nlm.nih.gov/42118136/). *Elife*. [Other]
Gao JL (2026). [PMID: 41505207](https://pubmed.ncbi.nlm.nih.gov/41505207/). *J Clin Invest*. [Gene Therapy / Novel Therapeutics]
Huynh L (2026). [PMID: 41936270](https://pubmed.ncbi.nlm.nih.gov/41936270/). *Curr Res Transl Med*. [Review / Meta-Analysis]
Miller RZ (2026). [PMID: 41451822](https://pubmed.ncbi.nlm.nih.gov/41451822/). *Curr Opin Allergy Clin Immunol*. [Review / Meta-Analysis]
Al Lohaibi R (2026). [PMID: 41629964](https://pubmed.ncbi.nlm.nih.gov/41629964/). *Allergy Asthma Clin Immunol*. [Basic Science / Preclinical]
McDermott DH (2026). [PMID: 41904735](https://pubmed.ncbi.nlm.nih.gov/41904735/). *J Clin Immunol*. [Case Report / Case Series]
Eisman SE (2026). [PMID: 42051299](https://pubmed.ncbi.nlm.nih.gov/42051299/). *bioRxiv*. [Basic Science / Preclinical]
Tulsiyan A (2026). [PMID: 42165386](https://pubmed.ncbi.nlm.nih.gov/42165386/). *Pediatr Dev Pathol*. [Case Report / Case Series]
Azuma Y (2026). [PMID: 41793776](https://pubmed.ncbi.nlm.nih.gov/41793776/). *Immunol Med*. [Case Report / Case Series]
Li J (2025). [PMID: 40239948](https://pubmed.ncbi.nlm.nih.gov/40239948/). *Lab Invest*. [Gene Therapy / Novel Therapeutics]
Data assembled from 8 of 12 sources · Last updated Sep 20, 2026, 3:03 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about WHIM syndrome 1
AI-curated news mentioning WHIM syndrome 1
Updated Aug 17, 2026
A recent study explores the audiologic and otolaryngologic phenotype in WHIM syndrome, providing insights into the clinical manifestations of this rare disease. The findings may enhance understanding and management of patients affected by WHIM syndrome.